← Back to Search

Mavacamten for Hypertrophic Cardiomyopathy (COMPASS-HCM Trial)

N/A
Recruiting
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline
Awards & highlights

Summary

This real-world study will assess changes in health status among participants with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mavacamten in the real world.

Eligible Conditions
  • Hypertrophic Cardiomyopathy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~weeks 2, 4, 8, 12, 24, 30, 48, 60, 72, 84 and 96
This trial's timeline: 3 weeks for screening, Varies for treatment, and weeks 2, 4, 8, 12, 24, 30, 48, 60, 72, 84 and 96 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Other pharmacological and surgical treatments for obstructive hypertrophic cardiomyopathy (HCM)
Participant Hypertrophic Cardiomyopathy symptoms as assessed by Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ v2,0 - 7-day recall version)
Participant change in symptom severity as assessed by Patient Global Impression of Change (PGI-C)
+7 more

Side effects data

From 2024 Phase 3 trial • 112 Patients • NCT04349072
9%
Fatigue
8%
Dizziness
7%
Headache
6%
Dyspnoea
6%
Palpitations
6%
Dyspnoea exertional
6%
Hypertension
6%
Arthralgia
3%
Atrial fibrillation
1%
Peripheral venous disease
1%
Cardiac failure congestive
1%
Acute respiratory failure
1%
Gastrooesophageal reflux disease
1%
Sudden cardiac death
1%
Fall
1%
Large intestine perforation
1%
Pneumatosis intestinalis
1%
Nephrolithiasis
1%
Pulmonary embolism
1%
COVID-19
1%
Clostridium difficile infection
100%
80%
60%
40%
20%
0%
Study treatment Arm
Mavacamten
Placebo

Trial Design

1Treatment groups
Experimental Treatment
Group I: MavacamtenExperimental Treatment1 Intervention
Adult participants with symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mavacamten
2022
Completed Phase 3
~450

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,678 Previous Clinical Trials
4,125,527 Total Patients Enrolled
~79 spots leftby Dec 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top